EGFR tyrosine kinase inhibitors (EGFR-TKIs) significantly enhance survival in patients with advanced EGFR-mutated NSCLC, with osimertinib, a third-generation EGFR-TKI, demonstrating superior survival benefits over first-generation EGFR-TKIs (Soria et al., 2018). Here, EGFR is linked to non-small cell lung carcinoma.